MedTrace Logo

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

NCT02810457 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 731

Last updated 2022-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

FKB238 (bevacizumab)

DRUG

Avastin (bevacizumab)

DRUG

Paclitaxel

DRUG

Carboplatin

Sponsors & Collaborators

  • Centus Biotherapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Centus Biotherapeutics Limited · Centus Biotherapeutics Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-07
Primary Completion
2019-01-24
Completion
2022-01-26

Countries

  • United States
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Georgia
  • Germany
  • Greece
  • Hungary
  • Italy
  • Japan
  • Peru
  • Philippines
  • Poland
  • Romania
  • Russia
  • Serbia
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02810457 on ClinicalTrials.gov